Venus Remedies Limited (VENUSREM.BO)
INR 325.25
(-0.15%)
INR 325.25
(-0.15%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 413.6 Million | 366.27 Million | 411.01 Million | 1.31 Billion | 776.04 Million | 453.27 Million |
| Net Income | 284.9 Million | 379.3 Million | 364.08 Million | 251.11 Million | 7.76 Million | -207.65 Million |
| Depreciation & Amortization | 264.39 Million | 322.97 Million | 335.33 Million | 352.76 Million | 320.12 Million | 339.8 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -121.1 Million | -246.33 Million | -216.37 Million | 613.91 Million | 208.22 Million | 53.68 Million |
| Other non-cash items | 514.2 Million | -89.67 Million | -72.02 Million | 100.58 Million | 239.92 Million | 267.44 Million |
| Investing Cash Flow | -113.8 Million | -508.29 Million | -167.26 Million | 564.93 Million | -47.48 Million | -113.32 Million |
| Investments in PPE | -135.2 Million | -78.18 Million | -137.07 Million | -77.27 Million | -77.8 Million | -99.24 Million |
| Acquisitions | 4.8 Million | 735 Thousand | 4.16 Million | 575.74 Million | - | - |
| Investment purchases | - | -453.63 Million | -46.02 Million | -24.37 Million | - | - |
| Sales/Maturities of investments | 12.7 Million | 84 Thousand | 141.07 Million | 77.27 Million | - | - |
| Other Investing Activities | 3.9 Million | 22.69 Million | -129.4 Million | 13.57 Million | 30.32 Million | -14.07 Million |
| Financing Cash Flow | -9.9 Million | -5.67 Million | -94.77 Million | -1.62 Billion | -730.02 Million | -351.67 Million |
| Debt repayment | -9.9 Million | -4.49 Million | -90.15 Million | -1.68 Billion | -609.37 Million | -127.99 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 137.52 Million | - | - |
| Other Financing Activities | -900 Thousand | -1.18 Million | -4.61 Million | -70.2 Million | -120.64 Million | -223.67 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -121.1 Million | -246.33 Million | -216.37 Million | 613.91 Million | 208.22 Million | 53.68 Million |
| Cash at beginning of period | 212.12 Million | 432.55 Million | 288.79 Million | 19.42 Million | 20.33 Million | 39.82 Million |
| Cash at end of period | 681 Million | 212.12 Million | 432.55 Million | 288.79 Million | 19.42 Million | 28.1 Million |
| Capital Expenditure | -135.2 Million | -78.18 Million | -137.07 Million | -77.27 Million | -77.8 Million | -99.24 Million |
| Effect of forex changes on cash | -12.6 Million | -72.73 Million | -5.21 Million | 8.48 Million | 556 Thousand | - |
| Net cash flow / Change in cash | 468.87 Million | -220.43 Million | 143.76 Million | 269.36 Million | -907 Thousand | -11.72 Million |
| Free Cash Flow | 278.4 Million | 288.09 Million | 273.94 Million | 1.24 Billion | 698.23 Million | 354.02 Million |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 12.2 Million | 105.2 Million | 284.9 Million | 68.5 Million | 99.4 Million | 11.8 Million |
| Depreciation & Amortization | - | - | 264.39 Million | 65.4 Million | 64.4 Million | 75.5 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | -121.1 Million | - | - | - |
| Other non-cash items | -12.2 Million | -105.2 Million | 514.2 Million | -68.5 Million | -99.4 Million | -11.8 Million |
| Investing Cash Flow | - | - | -113.8 Million | - | - | - |
| Investments in PPE | - | - | -135.2 Million | - | - | - |
| Acquisitions | - | - | 4.8 Million | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 12.7 Million | - | - | - |
| Other Investing Activities | - | - | 3.9 Million | - | - | - |
| Financing Cash Flow | - | - | -9.9 Million | - | - | - |
| Debt repayment | - | - | -9.9 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -900 Thousand | - | - | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | -121.1 Million | - | - | - |
| Cash at beginning of period | - | - | 212.12 Million | 676.8 Million | 577.4 Million | 212.12 Million |
| Cash at end of period | - | - | 681 Million | 807.6 Million | 676.8 Million | 11.8 Million |
| Capital Expenditure | - | - | -135.2 Million | - | - | - |
| Effect of forex changes on cash | - | - | -12.6 Million | - | - | - |
| Net cash flow / Change in cash | - | - | 468.87 Million | 130.8 Million | 99.4 Million | -200.32 Million |
| Free Cash Flow | - | - | 278.4 Million | 130.8 Million | 99.4 Million | 11.8 Million |
ATS
AEHR
688707
CRLA
2742
NOSA